Representative Issuers

Charlie has represented companies/investment banks on capital market transactions involving issuers across industries, such as: Accelerate, Advaxis, Aerohive Networks, Agenus, Akari, Akcea, Allogene, Alteryx, Amedica, Amylin, Anadys, AnaptysBio, Anthera, Apigee, Arcadia, Arcus, Ardea, Arena, Aridis, Ascendis, ASLAN, Audentes, AutoGenomics, Ballast Point Brewing & Spirits, Cadence, Castlight, Cerus, Cidara, Corcept, Crinetics, Cyan, Cytori, Dermira, Dynavax, eBay, Eidos, Entropic Communications, Evofem, FireEye, Five Prime, Gemphire, Genomatica, Global Blood Therapeutics, Gritstone, Guardant Health, Halozyme, HealthEquity, Horizon, Ignyta, Immune Design, Inovio, Insys, Invitae, Ionis, Iterum, Jazz Pharmaceuticals, Kamada, Kite Pharma, Landry's, LifeLock, Limelight Networks, MannKind, MethylGene, Metropark USA, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neurocrine, ObsEva, Ooma, Optimer, Otonomy, Pernix, PRA Holdings, Progressive Gaming, ProNAi, ProQR Therapeutics, Proto Labs, Quidel, Radiant Systems, Raptor Pharmaceutical, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sangamo, Santarus, Seattle Genetics, Senomyx, Sequenom, Siera Oncology, Somaxon, Strongbridge, Surface Oncology, Sutro Biopharma, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, TRACON, Tricida, Trius, TriVascular Technologies, Verenium, Verona, Vical, Viewray, Vital Therapies, Xencor, Xenon, XenoPort, Zealand Pharma, Zscaler and Zymeworks.